# Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma

> **NCT07734857** · — · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **OTHER:** No intervention (observational study)

## Key facts

- **NCT ID:** NCT07734857
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2028-07-10
- **Final completion:** 2028-07-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734857, "Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*